“I came out to raise awareness of IQVIA and publicize its role as a partner at a time when Korea’s biopharmaceutical industry is growing.”
IQVIA Korea, a company specializing in clinical and data development, participated in BIOKOREA 2023 for the first time this year and is actively communicating with the domestic biopharmaceutical industry.
As more and more companies consider entering the global market due to the rapid growth of biopharmaceuticals, IQVIA announced programs within IQVIA that can support them and set up contact points.
Bio Korea 2023 opened on the 10th and is being held for three days with various programs under the theme ‘Age of Hyper-Connectivity, Leap to New Growth Innovative Technology’. It celebrated its 18th anniversary this year, and included business partnering, an exhibition, a conference, and an investment fair with the participation of 730 companies from 51 countries.
An IQVIA official who came out to support the field said, “IQVIA is a company that provides services to pharmaceutical companies, so I participated to show what kind of service it has.” It’s a movement,” he said.
Looking at the booth, it included information on various services such as ▲ Research and Development Solution ▲ Tech Pharma Solution ▲ Real World Solution and Analytics ▲ Market Insights.
Although IQVIA is supported through various stages from the drug stage to clinical trials and post-marketing tracking, it was unfortunate that the awareness of each stage of the service was limited, so the main purpose is to inform each of them in comprehensive in one place.
In particular, as many new drug development companies consider strategies to shorten the development period to be as important as investment costs, their support for this was emphasized.
Among them, the publicity method that caught the eye was the kiosk consultation, which provided a service where visitors to the booth could make inquiries according to the area they wanted to consult, such as drug clinical development strategy and licensing strategy.
In addition, by making it possible to see and experience the AI technology implemented by Pharma Tech solutions, etc., many visitors came to the booth to increase understanding.
Ultimately, a strategy to achieve scalability in the domestic bio pharmaceutical industry from a long-term perspective through these contact points.
An IQVIA official said, “When we receive inquiries, there is a prejudice that IQVIA only works for large companies.” We will continue our efforts to achieve scalability.”
Meanwhile, on the 11th, IQVIA held an analysis session on the global status of classified clinical trials to find out the global trend of classified clinical trials and discuss ways to invigorate DCT in Korea.
